Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281692 · ClinicalTrials.gov registry record
Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )
A clinical trial of SARS-CoV-2, sponsored by Convergent Genomics.
- Completed
- Registry status
- 205
- Enrollment target
- 1
- Study location
NCT05281692 is a study of SARS-CoV-2 that has completed, run by Convergent Genomics. The registered enrollment target is 205 participants, below the 3,763-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05281692, a study of SARS-CoV-2, has completed, sponsored by Convergent Genomics.
- COMPLETED
- Registry status
- 205 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study to evaluate the clinical utility of the Enhanced Preservation Media with Integrated Extraction (EPM-IX)
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Enhanced Preservation Media (EPM-IX)
Study Locations (1)
Illinois
- UroPartners Urology Group - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2022-03-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05281692
The ClinicalTrials.gov registry entry for NCT05281692 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,763-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (95% lower). The listed sponsor is Convergent Genomics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 1 intervention - of which Enhanced Preservation Media (EPM-IX) is the first listed.
NCT05281692 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05281692 about?
NCT05281692 is a clinical study titled "Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )". This is a research study to evaluate the clinical utility of the Enhanced Preservation Media with Integrated Extraction (EPM-IX)
What is the current status of trial NCT05281692?
This trial is currently completed. The enrollment target is 205 participants. The study started on 2022-02-02. Estimated completion is 2022-03-21.
What conditions does trial NCT05281692 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT05281692?
The interventions under investigation include: Enhanced Preservation Media (EPM-IX) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05281692?
This trial is sponsored by Convergent Genomics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05281692 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
-
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RECRUITING · Phase 1
-
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.